Microcap Enveric Biosciences (NASDAQ:ENVB) is threatening to take legal action against AbbVie (NYSE:ABBV) as it believes that the latter’s major depressive disorder candidate bretisilocin, which it said it would acquire from Gilgamesh Pharmaceuticals in August for up to $1.2B, infringes on a patent it holds.
